Connect Biopharma to Present at Oppenheimer Healthcare Conference
Event summary
- Connect Biopharma will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 2:40 p.m. ET.
- The presentation will be webcast live and archived for 90 days on the company's investor relations website.
- Connect Biopharma is focused on treating inflammatory diseases, particularly asthma and COPD, with its lead candidate rademikibart.
- The company has an exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China, with potential milestone payments up to $110 million and tiered royalties.
The big picture
Connect Biopharma's presentation at the Oppenheimer conference underscores its focus on transforming care for inflammatory diseases through its lead candidate, rademikibart. The company's strategic partnership with Simcere Pharmaceutical highlights its efforts to penetrate the lucrative Greater China market, where significant unmet needs in asthma and COPD treatment exist. The potential milestone payments and royalties from this partnership could substantially impact Connect Biopharma's financial trajectory.
What we're watching
- Clinical Progress
- The pace at which Connect Biopharma advances its global clinical studies for rademikibart in treating asthma and COPD exacerbations.
- Market Strategy
- How the company leverages its partnership with Simcere Pharmaceutical to expand market reach in Greater China.
- Financial Performance
- Whether Connect Biopharma can achieve the remaining milestone payments and sustain royalty revenues from the Simcere agreement.
Related topics